Candel Therapeutics' CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial

By Proactive Investors / October 02, 2025 / www.youtube.com / Article Link


Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to highlight new subgroup analyses from the ...

Recent News

Big Gold still struggling overall in 2026

September 28, 2026 / www.canadianminingreport.com

Gold stocks down on metal price pullback

September 28, 2026 / www.canadianminingreport.com

Mining sector far outpaces tech over past three years

September 21, 2026 / www.canadianminingreport.com

Gold stocks down with GDXJ outperforming on rebalancing

September 21, 2026 / www.canadianminingreport.com

Copper slides as US apparently wavering on tariff hikes

September 14, 2026 / www.canadianminingreport.com
See all >
Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok